Berry-Jenkins, Joshua

Bond, Debbie

Boyle, Cathal

Brooksby, Alan

Cavill, Charlotte

Gaffney, Karl

Hamilton, Louise

Leeder, Jane

Lonsdale, Ellie

Sengupta, Raj

Yahya, Fariz

English

University of East Anglia digital repository

Letter to the Editor(matters arising from published papers)Rheumatology Advances in Practice 2018;0:1doi: 10.1093/rap/rky037Comment on: Tumour necrosis factor inhibitorsurvival and predictors of response in axialspondyloarthritis—findings from a UnitedKingdom cohort: replySIR, We thank Al Arashi et al. [1] for their interest andcomments on our recent report on tumour necrosis fac-tor inhibitor (TNFi) survival and predictors of response inaxial spondyloarthritis—findings from a United Kingdomcohort [2].We did not focus specifically on sex differences in ouranalysis but have now undertaken further analyses onsex differences in our study population. We found ahigher prevalence of acute anterior uveitis (44.9 vs33.9%, P¼0.03) and family history of SpA (45.2 vs30.4%, P¼ 0.02) in females, but not for IBD (females16.8% vs males 11.9%, P¼0.19) or psoriasis (females24.3% vs males 19.5%, P¼ 0.29). This is similar to pre-vious studies, which reported that women are more af-fected by uveitis in SpA [3] and AS [4].In our cohort, BASDAI50 response 3–6 months afterinitiation of index TNFi was achieved by 56 (58.3%)females and 219 (61.5%) males (P¼0.64).Discontinuation rates for index TNFi were higher infemales (females n¼56, 37.3%; males n¼ 168, 33.5%).In addition, females had higher rates of adverse events(44.6 vs 33.9%), and males had a slightly higher propor-tion of primary non-response (15.5 vs 14.3%) and sec-ondary non-response (20.8 vs 16.1%). None of thesedifferences reached statistical significance.In conclusion, there are differences between our co-hort and those reported by Al Arashi et al. [1]; however,sample sizes are small. Larger prospective studies arerequired to evaluate sex differences in axSpA.Funding: No specific funding was received from any fund-ing bodies in the public, commercial or not-for-profit sec-tors to carry out the work described in this manuscript.Disclosure statement: F.Y. has received funding to at-tend congresses and speakers fees from Novartis, Pfizerand AbbVie and has received grants and consultancyfrom Novartis. K.G. has received research grants,consultancy and speaker fees from AbbVie, Pfizer,Novartis and UCB Pharma. L.H. has received fundingfor attending congresses from UCB Pharma. C.B. hasreceived training grant from Arthritis Research UK, travelcosts to conference from AbbVie and conference feespaid by Pfizer. D.B. has received funding for attendingcongresses from Pfizer, AbbVie and Chugai, and is onadvisory boards for Roche, Chugai and Novartis. R.S.has received speakers fees, consultancy and/or grantsfrom AbbVie, Celgene, Merck Sharp & Dohme, Novartis,Pfizer and UCB Pharma. All other authors have declaredno conflicts of interest.Fariz Yahya1,2, Karl Gaffney3, Louise Hamilton3,Ellie Lonsdale3, Jane Leeder3, Alan Brooksby3,Charlotte Cavill1, Joshua Berry-Jenkins1,Cathal Boyle1, Debbie Bond1 and Raj Sengupta1,41Department of Rheumatology, Royal National Hospital forRheumatic Diseases, Bath, UK, 2Department of Medicine,University Malaya, Kuala Lumpur, Malaysia, 3Departmentof Rheumatology, Norfolk and Norwich University HospitalNHS Foundation Trust, Norwich and 4Department ofPharmacology, University of Bath, Bath, UKAccepted 10 August 2018Correspondence to: Fariz Yahya, Royal National Hospitalfor Rheumatic Diseases, Upper Borough Walls, Bath BA11RL, UK. E-mail: drfarizyahya@gmail.comReferences1 Al Arashi W, Hensor EM, Gaffney K et al. Comment on:tumour necrosis factor inhibitor survival and predictorsof response in axial spondyloarthritis—findings from aUnited Kingdom cohort. Rheumatology Advances inPractice 2018; doi:10.1093/rap/rky036.2 Yahya F, Gaffney K, Hamilton L et al. Tumour necrosisfactor inhibitor survival and predictors of response in ax-ial spondyloarthritis—findings from a United Kingdomcohort. Rheumatology 2018;57:619–24.3 Zeboulon N, Dougados M, Gossec L. Prevalence and char-acteristics of uveitis in the spondyloarthropathies: a system-atic literature review. Ann Rheum Dis 2008;67:955–9.4 Kim TJ, Kim TH. Clinical spectrum of ankylosing spondy-litis in Korea. Joint Bone Spine 2010;77:235–40.LETTERVC The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.comRheumatology Advances in PracticeDownloaded from https://academic.oup.com/rheumap/article/2/2/rky037/5135285 by University of East Anglia user on 24 August 2020

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort: reply

https://ueaeprints.uea.ac.uk/id/eprint/76577/1/Published_Version.pdf

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort: reply

Abstract

Similar works

Full text

Available Versions

University of East Anglia digital repository